PARLIAMENTARY WRITTEN QUESTION
Cervical Cancer: Screening (11 February 2021)
Question Asked
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of using mRNA-based HPV tests in primary cervical cancer screening.
Asked by:
Mike Kane (Labour)
Asked by:
Mike Kane (Labour)
Answer
The National Cervical Screening Programme uses both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) based human papillomavirus (HPV) testing in the programme.
Laboratories can choose to use either the DNA or RNA HPV testing methods as both are approved.
The United Kingdom National Screening Committee has received a proposal to consider the use of digital pathology in the cancer screening programmes and work to assess this is under way.
Answered by:
Jo Churchill (Conservative)
23 February 2021
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.